Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro

Masato Asanuma, Ikuko Miyazaki, Francisco J. Diaz-Corrales, Masako Shimizu, Ken Ichi Tanaka, Norio Ogawa

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objectives and methods: To clarify the effects of a non-ergot dopamine agonist pramipexole on levodopa-induced abnormal dopamine metabolism in the parkinsonian model, we examined striatal changes in dopamine and its metabolites after repeated administration of pramipexole and/or levodopa using 6-hydroxydopamine-lesioned hemi-parkinsonian mice. Moreover, the effects of pramipexole on dopamine-semiquinones were also accessed using an in vitro dopamine-semiquinone generating system to elucidate its neuroprotective property against dopamine quinone-induced neurotoxicity that appears as dopamine neuron-specific oxidative stress. Results: Combined administration of pramipexole (0.5 or 1 mg/kg/day, 7 days) selectively suppressed the levodopa-induced (50 mg/kg/day) increase of striatal dopamine turnover in the parkinsonian side, but not in the non-lesioned side. In addition to the antioxidant properties previously reported, it was clarified that pramipexole scavenged dopamine-semiquinones generated in a dose-dependent manner either in simultaneous incubation or post-incubation. Discussion: The neurotoxicity of dopamine quinones that appear as dopaminergic neuron-specific oxidative stress has recently been known to play a role in the pathogenesis of Parkinson's disease and neurotoxin-induced parkinsonism. Therefore, the present results revealed that pramipexole possesses neuroprotective effects against abnormal dopamine metabolism in excessively levodopa-administered parkinsonian brains and against cytotoxic dopamine quinones generated from excess dopamine, preventing consequently dopaminergic neuronal damage induced by excess dopamine or levodopa.

Original languageEnglish
Pages (from-to)533-539
Number of pages7
JournalNeurological Research
Volume27
Issue number5
DOIs
Publication statusPublished - Jul 2005

Fingerprint

Levodopa
Dopamine
Corpus Striatum
Dopaminergic Neurons
Oxidative Stress
pramipexole
In Vitro Techniques
Oxidopamine
Dopamine Agonists
Neurotoxins
Parkinsonian Disorders
Neuroprotective Agents
Parkinson Disease
Antioxidants
Brain

Keywords

  • Dopamine quinone
  • Dopamine turnover
  • Levodopa
  • Parkinson's disease
  • Pramipexole

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro. / Asanuma, Masato; Miyazaki, Ikuko; Diaz-Corrales, Francisco J.; Shimizu, Masako; Tanaka, Ken Ichi; Ogawa, Norio.

In: Neurological Research, Vol. 27, No. 5, 07.2005, p. 533-539.

Research output: Contribution to journalArticle

@article{5b54d824dd1c46ac81a643f57c809898,
title = "Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro",
abstract = "Objectives and methods: To clarify the effects of a non-ergot dopamine agonist pramipexole on levodopa-induced abnormal dopamine metabolism in the parkinsonian model, we examined striatal changes in dopamine and its metabolites after repeated administration of pramipexole and/or levodopa using 6-hydroxydopamine-lesioned hemi-parkinsonian mice. Moreover, the effects of pramipexole on dopamine-semiquinones were also accessed using an in vitro dopamine-semiquinone generating system to elucidate its neuroprotective property against dopamine quinone-induced neurotoxicity that appears as dopamine neuron-specific oxidative stress. Results: Combined administration of pramipexole (0.5 or 1 mg/kg/day, 7 days) selectively suppressed the levodopa-induced (50 mg/kg/day) increase of striatal dopamine turnover in the parkinsonian side, but not in the non-lesioned side. In addition to the antioxidant properties previously reported, it was clarified that pramipexole scavenged dopamine-semiquinones generated in a dose-dependent manner either in simultaneous incubation or post-incubation. Discussion: The neurotoxicity of dopamine quinones that appear as dopaminergic neuron-specific oxidative stress has recently been known to play a role in the pathogenesis of Parkinson's disease and neurotoxin-induced parkinsonism. Therefore, the present results revealed that pramipexole possesses neuroprotective effects against abnormal dopamine metabolism in excessively levodopa-administered parkinsonian brains and against cytotoxic dopamine quinones generated from excess dopamine, preventing consequently dopaminergic neuronal damage induced by excess dopamine or levodopa.",
keywords = "Dopamine quinone, Dopamine turnover, Levodopa, Parkinson's disease, Pramipexole",
author = "Masato Asanuma and Ikuko Miyazaki and Diaz-Corrales, {Francisco J.} and Masako Shimizu and Tanaka, {Ken Ichi} and Norio Ogawa",
year = "2005",
month = "7",
doi = "10.1179/016164105X22093",
language = "English",
volume = "27",
pages = "533--539",
journal = "Neurological Research",
issn = "0161-6412",
publisher = "Maney Publishing",
number = "5",

}

TY - JOUR

T1 - Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro

AU - Asanuma, Masato

AU - Miyazaki, Ikuko

AU - Diaz-Corrales, Francisco J.

AU - Shimizu, Masako

AU - Tanaka, Ken Ichi

AU - Ogawa, Norio

PY - 2005/7

Y1 - 2005/7

N2 - Objectives and methods: To clarify the effects of a non-ergot dopamine agonist pramipexole on levodopa-induced abnormal dopamine metabolism in the parkinsonian model, we examined striatal changes in dopamine and its metabolites after repeated administration of pramipexole and/or levodopa using 6-hydroxydopamine-lesioned hemi-parkinsonian mice. Moreover, the effects of pramipexole on dopamine-semiquinones were also accessed using an in vitro dopamine-semiquinone generating system to elucidate its neuroprotective property against dopamine quinone-induced neurotoxicity that appears as dopamine neuron-specific oxidative stress. Results: Combined administration of pramipexole (0.5 or 1 mg/kg/day, 7 days) selectively suppressed the levodopa-induced (50 mg/kg/day) increase of striatal dopamine turnover in the parkinsonian side, but not in the non-lesioned side. In addition to the antioxidant properties previously reported, it was clarified that pramipexole scavenged dopamine-semiquinones generated in a dose-dependent manner either in simultaneous incubation or post-incubation. Discussion: The neurotoxicity of dopamine quinones that appear as dopaminergic neuron-specific oxidative stress has recently been known to play a role in the pathogenesis of Parkinson's disease and neurotoxin-induced parkinsonism. Therefore, the present results revealed that pramipexole possesses neuroprotective effects against abnormal dopamine metabolism in excessively levodopa-administered parkinsonian brains and against cytotoxic dopamine quinones generated from excess dopamine, preventing consequently dopaminergic neuronal damage induced by excess dopamine or levodopa.

AB - Objectives and methods: To clarify the effects of a non-ergot dopamine agonist pramipexole on levodopa-induced abnormal dopamine metabolism in the parkinsonian model, we examined striatal changes in dopamine and its metabolites after repeated administration of pramipexole and/or levodopa using 6-hydroxydopamine-lesioned hemi-parkinsonian mice. Moreover, the effects of pramipexole on dopamine-semiquinones were also accessed using an in vitro dopamine-semiquinone generating system to elucidate its neuroprotective property against dopamine quinone-induced neurotoxicity that appears as dopamine neuron-specific oxidative stress. Results: Combined administration of pramipexole (0.5 or 1 mg/kg/day, 7 days) selectively suppressed the levodopa-induced (50 mg/kg/day) increase of striatal dopamine turnover in the parkinsonian side, but not in the non-lesioned side. In addition to the antioxidant properties previously reported, it was clarified that pramipexole scavenged dopamine-semiquinones generated in a dose-dependent manner either in simultaneous incubation or post-incubation. Discussion: The neurotoxicity of dopamine quinones that appear as dopaminergic neuron-specific oxidative stress has recently been known to play a role in the pathogenesis of Parkinson's disease and neurotoxin-induced parkinsonism. Therefore, the present results revealed that pramipexole possesses neuroprotective effects against abnormal dopamine metabolism in excessively levodopa-administered parkinsonian brains and against cytotoxic dopamine quinones generated from excess dopamine, preventing consequently dopaminergic neuronal damage induced by excess dopamine or levodopa.

KW - Dopamine quinone

KW - Dopamine turnover

KW - Levodopa

KW - Parkinson's disease

KW - Pramipexole

UR - http://www.scopus.com/inward/record.url?scp=22844432474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22844432474&partnerID=8YFLogxK

U2 - 10.1179/016164105X22093

DO - 10.1179/016164105X22093

M3 - Article

VL - 27

SP - 533

EP - 539

JO - Neurological Research

JF - Neurological Research

SN - 0161-6412

IS - 5

ER -